Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 240.22
OGXI's Cash-to-Debt is ranked higher than
53% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OGXI: 240.22 )
Ranked among companies with meaningful Cash-to-Debt only.
OGXI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.88  Med: 26.67 Max: No Debt
Current: 240.22
Interest Coverage N/A
OGXI's Interest Coverage is ranked lower than
53% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OGXI: N/A )
Ranked among companies with meaningful Interest Coverage only.
OGXI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: -7.11
Beneish M-Score: 2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -191.16
OGXI's Operating Margin % is ranked lower than
58% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. OGXI: -191.16 )
Ranked among companies with meaningful Operating Margin % only.
OGXI' s Operating Margin % Range Over the Past 10 Years
Min: -418.65  Med: -108.67 Max: -10.11
Current: -191.16
-418.65
-10.11
Net Margin % -181.57
OGXI's Net Margin % is ranked lower than
58% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. OGXI: -181.57 )
Ranked among companies with meaningful Net Margin % only.
OGXI' s Net Margin % Range Over the Past 10 Years
Min: -397.65  Med: -96.77 Max: -21.44
Current: -181.57
-397.65
-21.44
ROE % -70.24
OGXI's ROE % is ranked lower than
68% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. OGXI: -70.24 )
Ranked among companies with meaningful ROE % only.
OGXI' s ROE % Range Over the Past 10 Years
Min: -73.64  Med: -41.29 Max: -28.99
Current: -70.24
-73.64
-28.99
ROA % -47.52
OGXI's ROA % is ranked lower than
61% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. OGXI: -47.52 )
Ranked among companies with meaningful ROA % only.
OGXI' s ROA % Range Over the Past 10 Years
Min: -47.52  Med: -25.55 Max: -13.07
Current: -47.52
-47.52
-13.07
ROC (Joel Greenblatt) % -4331.97
OGXI's ROC (Joel Greenblatt) % is ranked lower than
78% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. OGXI: -4331.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OGXI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18547.17  Med: -4474.56 Max: -230.97
Current: -4331.97
-18547.17
-230.97
3-Year Revenue Growth Rate -56.40
OGXI's 3-Year Revenue Growth Rate is ranked lower than
86% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. OGXI: -56.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OGXI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.4 Max: 637
Current: -56.4
0
637
3-Year EBITDA Growth Rate -33.30
OGXI's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. OGXI: -33.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OGXI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -74.3  Med: -10.9 Max: 104.5
Current: -33.3
-74.3
104.5
3-Year EPS without NRI Growth Rate -32.40
OGXI's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OGXI: -32.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OGXI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73.5  Med: -1.3 Max: 87.8
Current: -32.4
-73.5
87.8
GuruFocus has detected 4 Warning Signs with OncoGenex Pharmaceuticals Inc $OGXI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OGXI's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OGXI Guru Trades in Q1 2016

Jim Simons 806,700 sh (+6.57%)
» More
Q2 2016

OGXI Guru Trades in Q2 2016

Jim Simons 876,100 sh (+8.60%)
» More
Q3 2016

OGXI Guru Trades in Q3 2016

Jim Simons 908,100 sh (+3.65%)
» More
Q4 2016

OGXI Guru Trades in Q4 2016

Jim Simons 1,034,500 sh (+13.92%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:APTO, NAS:KTOV, OTCPK:OPNT, NAS:OCRX, NAS:CYCC, NAS:MBVX, OTCPK:BCTXF, OTCPK:PPGNY, OTCPK:ATTBF, NAS:GNVC, OTCPK:MATN, NAS:ORPN, NAS:SNGX, NAS:DPRX, NAS:SBOT, NAS:CBLI, NAS:JAGX, NAS:VTGN, OTCPK:PRGB, OTCPK:NULF » details
Traded in other countries:SP4A.Germany,
OncoGenex Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the development & commercialization of therapies that address treatment resistance in cancer patients. It has three product candidates including custirsen, apatorsen & OGX-225.

OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. The Company has three product candidates in pipeline including custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a opportunity for cancer drug development. Of the product candidates in pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two phase 3 studies and five phase 2 studies. The Company's product candidate's custirsen, apatorsen and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments. Custirsen is currently being evaluated in two phase 3 trials; one in patients with prostate cancer and one in patients with non-small cell lung cancer, or NSCLC. Custirsen is designed to inhibit the production of clusterin, a protein that promotes survival of cancer cells when overexpressed in a variety of tumors. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that affect the growth of cancer cells when overexpressed. The Company faces competition from pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products designed to address cancer indications. The Company owns trademarks registered in the United States, namely word marks ONCOGENEX, ORCA, Spruce, and Rainier, and design marks ORCA, Cedar, Pacific, Borealis-1, Borealis-2, and the helical totem element that accompanies the clinical trial trademarked identifiers. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country.

Ratios

vs
industry
vs
history
PB Ratio 0.77
OGXI's PB Ratio is ranked higher than
93% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. OGXI: 0.77 )
Ranked among companies with meaningful PB Ratio only.
OGXI' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.66 Max: 9
Current: 0.77
0.3
9
PS Ratio 1.22
OGXI's PS Ratio is ranked higher than
93% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. OGXI: 1.22 )
Ranked among companies with meaningful PS Ratio only.
OGXI' s PS Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.42 Max: 46.38
Current: 1.22
0.03
46.38
EV-to-EBIT 0.52
OGXI's EV-to-EBIT is ranked higher than
89% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. OGXI: 0.52 )
Ranked among companies with meaningful EV-to-EBIT only.
OGXI' s EV-to-EBIT Range Over the Past 10 Years
Min: -345.7  Med: -2.4 Max: 15.9
Current: 0.52
-345.7
15.9
EV-to-EBITDA 0.53
OGXI's EV-to-EBITDA is ranked higher than
90% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. OGXI: 0.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
OGXI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -438.5  Med: -2.4 Max: 15.8
Current: 0.53
-438.5
15.8
Current Ratio 3.22
OGXI's Current Ratio is ranked lower than
59% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OGXI: 3.22 )
Ranked among companies with meaningful Current Ratio only.
OGXI' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 3.31 Max: 12.9
Current: 3.22
1.87
12.9
Quick Ratio 3.22
OGXI's Quick Ratio is ranked lower than
55% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OGXI: 3.22 )
Ranked among companies with meaningful Quick Ratio only.
OGXI' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 3.31 Max: 12.9
Current: 3.22
1.87
12.9
Days Sales Outstanding 15.74
OGXI's Days Sales Outstanding is ranked higher than
83% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. OGXI: 15.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
OGXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.28  Med: 32.81 Max: 105.74
Current: 15.74
0.28
105.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.90
OGXI's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. OGXI: -26.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OGXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: -26.7 Max: -3.4
Current: -26.9
-67.6
-3.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.86
OGXI's Price-to-Net-Cash is ranked higher than
96% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. OGXI: 0.86 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OGXI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.77  Med: 4.12 Max: 10.23
Current: 0.86
0.77
10.23
Price-to-Net-Current-Asset-Value 0.77
OGXI's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. OGXI: 0.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OGXI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.74  Med: 3.6 Max: 17.04
Current: 0.77
0.74
17.04
Price-to-Tangible-Book 0.76
OGXI's Price-to-Tangible-Book is ranked higher than
95% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. OGXI: 0.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OGXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51  Med: 3.5 Max: 15.47
Current: 0.76
0.51
15.47
Price-to-Median-PS-Value 0.35
OGXI's Price-to-Median-PS-Value is ranked higher than
63% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. OGXI: 0.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OGXI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 2.62 Max: 831.27
Current: 0.35
0.03
831.27
Earnings Yield (Greenblatt) % 195.94
OGXI's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. OGXI: 195.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OGXI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.3  Med: 112.1 Max: 116330.9
Current: 195.94
6.3
116330.9

More Statistics

Revenue (TTM) (Mil) $11.09
EPS (TTM) $ -0.66
Beta2.94
Short Percentage of Float2.97%
52-Week Range $0.33 - 1.42
Shares Outstanding (Mil)30.09
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
George Soros Had A Mixed Day On The Market Oct 30 2014 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
OncoGenex Pharmaceuticals, Inc. :OGXI-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual... Mar 08 2017
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual... Mar 08 2017
ONCOGENEX PHARMACEUTICALS, INC. Financials Mar 01 2017
Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the... Mar 01 2017
Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the... Mar 01 2017
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 28 2017
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016 Feb 23 2017
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016 Feb 23 2017
Q4 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close Feb 23 2017
OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented... Feb 21 2017
OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented... Feb 21 2017
OncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017 Feb 16 2017
OncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017 Feb 16 2017
Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold... Jan 26 2017
After reverse takeover, Bothell's OncoGenex changes name, focuses on smoking cessation drug Jan 17 2017
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement Jan 05 2017
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)